Venus Concept Reports Fourth Quarter and Fiscal Year 2020 Financial Results; Reaffirms Fiscal Year 2021 Revenue Guidance
Venus Concept (NASDAQ: VERO) reported Q4 2020 revenue of $25.8 million, down 19% YoY from $31.9 million, impacted by COVID-19. However, it marked a 25% increase from Q3 2020's $20.7 million. The operating loss decreased by 42% YoY to $10.3 million, with a net loss of $15.0 million, improving from $22.7 million in Q4 2019. Adjusted EBITDA loss was $2.4 million, compared to $11.5 million the previous year. For 2021, guidance suggests revenue growth of 26% to 32%, assuming no significant COVID-19 resurgence. Cash stood at $34.4 million as of December 31, 2020.
- Q4 2020 revenue increased by 25% compared to Q3 2020.
- Operating loss reduced by 42% YoY, reflecting improved cost management.
- Adjusted EBITDA loss decreased significantly from Q4 2019.
- Expectations for 2021 revenue growth of 26% to 32% YoY.
- Q4 2020 total revenue decreased by 19% YoY.
- Net loss increased to $15.0 million from $22.7 million YoY.
- Total revenue for FY 2020 decreased by 29.3% to $78.0 million.
TORONTO, March 29, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2020.
Fourth Quarter 2020 Financial Summary:
- Total GAAP revenue for the fourth quarter of 2020 decreased
19% year-over-year, to$25.8 million , compared to$31.9 million for the fourth quarter 2019, driven by the negative impact of the COVID-19 global pandemic on our business. - Total GAAP revenue for the fourth quarter of 2020 increased
25% , compared to$20.7 million for the third quarter of 2020. - GAAP operating loss for the fourth quarter of 2020 was
$10.3 million , compared to a loss of$17.9 million for the fourth quarter of 2019, a decrease in operating loss of$7.6 million , or42% , year-over-year. - GAAP net loss for the fourth quarter of 2020 of
$15.0 million , compared to a loss of$22.7 million for the fourth quarter of 2019, a decrease in net loss of$7.7 million , or34% , year-over-year. - Adjusted EBITDA loss of
$2.4 million for the fourth quarter of 2020, compared to Adjusted EBITDA loss of$11.5 million in the fourth quarter of 2019, a decrease in adjusted EBITDA loss of$9.1 million year-over-year. - The Company had
$34.4 million and$15.7 million of cash and cash equivalents as of December 31, 2020 and December 31, 2019, respectively, and total debt obligations of approximately$79.6 million and$69.0 million as of December 31, 2020 and December 31, 2019, respectively.
Management Commentary:
“We continued to see improvements in business trends during the fourth quarter as customers in our key markets around the world continue to recover,” said Domenic Serafino, Chief Executive Officer of Venus Concept. “Fourth quarter sales increased
Mr. Serafino continued: “Our fourth quarter financial results reflect strong execution of our plan to balance our operating expense management, while continuing to make strategic investments, specifically in the North American market, to better-position us for profitable growth in the years to come. In the fourth quarter of 2020, we reduced our GAAP operating expenses by
Fourth Quarter and Fiscal Year 2020 Revenue by Region and by Product Type:
| Venus Concept Inc. | ||||||||||||||||||||||||||||
| Supplemental Financial Information - Revenue by Geographic Area | ||||||||||||||||||||||||||||
| Three months ended December 31, | Increase / (decrease) | Twelve months ended December 31, | Increase / (decrease) | |||||||||||||||||||||||||
| (Dollars in millions) | 2020 | 2019 | $ | % | 2020 | 2019 | $ | % | ||||||||||||||||||||
| United States | $ | 11.6 | $ | 16.4 | $ | (4.7 | ) | (28.9 | ) | % | $ | 34.0 | $ | 47.7 | $ | (13.7 | ) | (28.8 | ) | % | ||||||||
| International | 14.2 | 15.5 | (1.3 | ) | (8.3 | ) | % | 44.0 | 62.7 | (18.7 | ) | (29.8 | ) | % | ||||||||||||||
| Total | $ | 25.8 | $ | 31.9 | $ | (6.0 | ) | (18.9 | ) | % | $ | 78.0 | $ | 110.4 | $ | (32.4 | ) | (29.3 | ) | % | ||||||||
*numbers may not foot due to rounding.
| Venus Concept Inc. | ||||||||||||||||||||||||||||
| Supplemental Financial Information - Revenue by Type | ||||||||||||||||||||||||||||
| Three months ended December 31, | Increase / (decrease) | Twelve months ended December 31, | Increase / (decrease) | |||||||||||||||||||||||||
| (Dollars in millions) | 2020 | 2019 | $ | % | 2020 | 2019 | $ | % | ||||||||||||||||||||
| Lease revenue | $ | 9.7 | $ | 16.4 | $ | (6.6 | ) | (40.6 | ) | % | $ | 33.4 | $ | 65.2 | $ | (31.7 | ) | (48.7 | ) | % | ||||||||
| System revenue | 11.2 | 10.5 | 0.7 | 6.2 | % | 29.0 | 31.7 | (2.8 | ) | (8.7 | ) | % | ||||||||||||||||
| Product revenue | 3.7 | 2.8 | 0.9 | 31.7 | % | 10.9 | 6.9 | 3.9 | 56.4 | % | ||||||||||||||||||
| Service revenue | 1.2 | 2.1 | (0.9 | ) | (44.1 | ) | % | 4.8 | 6.6 | (1.8 | ) | (27.3 | ) | % | ||||||||||||||
| Total | $ | 25.8 | $ | 31.9 | $ | (6.0 | ) | (18.9 | ) | % | $ | 78.0 | $ | 110.4 | $ | (32.4 | ) | (29.3 | ) | % | ||||||||
*numbers may not foot due to rounding.
Fourth Quarter 2020 Financial Results:
Total revenue for the fourth quarter of 2020 decreased
The decrease in revenue was a result of decreased revenue in the United States of
The decrease in total revenue, by product category, for the fourth quarter of 2020 was driven by a decrease of
The increase in system revenue for the fourth quarter of 2020 was driven by a significant contribution of revenue from the sale of ARTAS® and ARTAS iX® systems, compared to the prior year period which only included contributions from the sale of ARTAS® and ARTAS iX® systems revenue following the closing of our merger on November 7, 2019. The increase in other product revenue was driven by sales of ARTAS procedure kits, only contributed to other product revenue for a partial period in the fourth quarter of 2019. The decrease in service revenue for the fourth quarter of 2020 was driven by COVID-19 related restrictions imposed by federal, state, and local governments resulting in a decline in VeroGrafters™ technician services, along with the suspension of operations of the 2two5 marketing services, offset by additional warranty revenue on ARTAS® systems.
Gross profit for the fourth quarter of 2020 decreased
Operating expenses for the fourth quarter of 2020 decreased
Operating loss for the fourth quarter of 2020 was
Net loss attributable to Venus Concept Inc. stockholders for the fourth quarter of 2020 was
Adjusted EBITDA loss for the fourth quarter of 2020 was
Fiscal Year 2020 Financial Results:
Total revenue decreased by
Net loss attributable to Venus Concept Inc. stockholders for the year ended December 31, 2020 was
Adjusted EBITDA loss for the year ended December 31, 2020 was
Fiscal Year 2021 Revenue Guidance:
Assuming no significant and persistent resurgence of COVID-19 and related lockdown measures in key markets that would negatively impact the Company’s customer base, and based on a notable increase in pipeline activity, the Company continues to expect total revenue for the twelve months ending December 31, 2021 in the range of
Conference Call Details:
Management will host a conference call at 5:00 p.m. Eastern Time on March 29, 2021 to discuss the results of the quarter and fiscal year with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13715787. A live webcast of the call will also be provided on the investor relations section of the Company's website at ir.venusconcept.com.
For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13715787. The webcast will be archived at ir.venusconcept.com.
About Venus Concept
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 20 direct markets. Venus Concept focuses its product sales strategy on a subscription-based business model in North America and in its well-established direct global markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Freeze Plus, Venus Heal, Venus Glow, Venus Bliss, Venus Epileve and Venus Viva MD. Venus Concept’s hair restoration systems includes NeoGraft®, an automated hair restoration system that facilitates the harvesting of follicles during a FUE process and the ARTAS® and ARTAS iX® Robotic Hair Restoration systems, which harvest follicular units directly from the scalp and create recipient implant sites using proprietary algorithms. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, and Aperture Venture Partners.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “1933 Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “1934 Act”). Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements include, but are not limited to, statements about the expected synergies and cost savings from our merger with Venus Concept Ltd.; our financial performance; the growth in demand for our systems and other products; and general economic conditions, including the global economic impact of COVID-19, involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which the Company operates and management's beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under Part I Item 1A—“Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, the Company does not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.
| Venus Concept Inc. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (In thousands of U.S. dollars, except share and per share data) | ||||||||
| Year Ended, December 31, | ||||||||
| 2020 | 2019 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 34,297 | $ | 15,666 | ||||
| Restricted cash | 83 | 83 | ||||||
| Accounts receivable, net of allowance of | 52,764 | 58,977 | ||||||
| Inventories | 17,759 | 18,844 | ||||||
| Deferred expenses | — | 59 | ||||||
| Prepaid expenses | 2,240 | 2,523 | ||||||
| Advances to suppliers | 2,587 | 450 | ||||||
| Other current assets | 5,674 | 3,101 | ||||||
| Total current assets | 115,404 | 99,703 | ||||||
| LONG-TERM ASSETS: | ||||||||
| Long-term receivables | 21,148 | 35,656 | ||||||
| Deferred tax assets | 884 | 622 | ||||||
| Severance pay funds | 685 | 710 | ||||||
| Property and equipment, net | 3,539 | 4,648 | ||||||
| Intangible assets | 18,865 | 22,338 | ||||||
| Goodwill | — | 27,450 | ||||||
| Total long-term assets | 45,121 | 91,424 | ||||||
| TOTAL ASSETS | $ | 160,525 | $ | 191,127 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Line of credit | $ | — | $ | 7,789 | ||||
| Trade payables | 6,322 | 9,401 | ||||||
| Accrued expenses and other current liabilities | 20,253 | 21,120 | ||||||
| Income taxes payable | 1,132 | 2,172 | ||||||
| Unearned interest income | 1,950 | 3,942 | ||||||
| Warranty accrual | 1,106 | 1,254 | ||||||
| Deferred revenues | 1,752 | 2,495 | ||||||
| Total current liabilities | 32,515 | 48,173 | ||||||
| LONG-TERM LIABILITIES: | ||||||||
| Long-term debt | 75,491 | 61,229 | ||||||
| Government assistance loans | 4,110 | — | ||||||
| Income tax payable | 478 | — | ||||||
| Accrued severance pay | 755 | 827 | ||||||
| Deferred tax liabilities | 811 | 1,017 | ||||||
| Unearned interest income | 1,778 | 1,681 | ||||||
| Warranty accrual | 533 | 723 | ||||||
| Other long-term liabilities | 293 | 799 | ||||||
| Total long-term liabilities | 84,249 | 66,276 | ||||||
| TOTAL LIABILITIES | 116,764 | 114,449 | ||||||
| Commitments and Contingencies (Note 9) | ||||||||
| STOCKHOLDERS’ EQUITY (Note 1): | ||||||||
| Common Stock, | 26 | 24 | ||||||
| Additional paid-in capital (Note 1) | 201,598 | 149,840 | ||||||
| Accumulated deficit | (157,392 | ) | (75,686 | ) | ||||
| TOTAL STOCKHOLDERS’ EQUITY | 44,232 | 74,178 | ||||||
| Non-controlling interests | (471 | ) | 2,500 | |||||
| 43,761 | 76,678 | |||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 160,525 | $ | 191,127 | ||||
| Venus Concept Inc. | ||||||||||||||||
| Consolidated Statement of Operations | ||||||||||||||||
| (In thousands of U.S. dollars, except per share data) | ||||||||||||||||
| Three months ended December 31, | Year ended December 31, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Revenue | ||||||||||||||||
| Leases | $ | 9,719 | $ | 16,358 | $ | 33,428 | $ | 65,170 | ||||||||
| Products and services | 16,111 | 15,496 | 44,586 | 45,236 | ||||||||||||
| 25,830 | 31,854 | 78,014 | 110,406 | |||||||||||||
| Cost of goods sold | ||||||||||||||||
| Leases | 2,603 | 3,147 | 7,899 | 13,411 | ||||||||||||
| Products and services | 6,516 | 8,961 | 18,724 | 20,342 | ||||||||||||
| 9,119 | 12,108 | 26,623 | 33,753 | |||||||||||||
| Gross profit | 16,711 | 19,746 | 51,391 | 76,653 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling and marketing | 7,390 | 12,426 | 26,203 | 41,409 | ||||||||||||
| General and administrative | 17,919 | 22,851 | 57,882 | 57,488 | ||||||||||||
| Research and development | 1,711 | 2,367 | 7,754 | 8,034 | ||||||||||||
| Goodwill impairment | - | - | 27,450 | - | ||||||||||||
| Total operating expenses | 27,020 | 37,644 | 119,289 | 106,931 | ||||||||||||
| Loss from operations | (10,309 | ) | (17,898 | ) | (67,898 | ) | (30,278 | ) | ||||||||
| Other expenses: | ||||||||||||||||
| Foreign exchange (gain) loss | (4,277 | ) | 2,202 | (68 | ) | 2,611 | ||||||||||
| Finance expenses | 1,821 | 1,645 | 8,343 | 7,549 | ||||||||||||
| Loss on debt extinguishment | 2,938 | - | 2,938 | - | ||||||||||||
| Loss on disposal of subsidiaries | 2,047 | - | 2,526 | - | ||||||||||||
| Loss before income taxes | (12,838 | ) | (21,745 | ) | (81,637 | ) | (40,438 | ) | ||||||||
| Income tax expense | 2,191 | 990 | 1,181 | 1,857 | ||||||||||||
| Net loss | (15,029 | ) | (22,735 | ) | (82,818 | ) | (42,295 | ) | ||||||||
| Deemed dividend | - | - | 3,564 | - | ||||||||||||
| Loss attributable to stockholders of the Company | (14,685 | ) | (20,796 | ) | (85,270 | ) | (40,619 | ) | ||||||||
| Loss attributable to non-controlling interest | (344 | ) | (1,939 | ) | (1,112 | ) | (1,676 | ) | ||||||||
| Net loss per share: | ||||||||||||||||
| Basic | $ | (0.34 | ) | $ | (1.07 | ) | $ | (2.33 | ) | $ | (4.77 | ) | ||||
| Diluted | (0.34 | ) | (1.07 | ) | (2.33 | ) | (4.77 | ) | ||||||||
| Weighted-average number of shares used in per share calculation: | ||||||||||||||||
| Basic | 42,802 | 19,511 | 36,626 | 8,517 | ||||||||||||
| Diluted | 42,802 | 19,511 | 36,626 | 8,517 | ||||||||||||
Use of Non-GAAP Financial Measures
Adjusted EBITDA is a non-GAAP measure defined as net loss income before foreign exchange loss, financial expenses, income tax expense, depreciation and amortization, stock-based compensation and non-recurring items for a given period. Adjusted EBITDA is not a measure of our financial performance under U.S. GAAP and should not be considered an alternative to net income or any other performance measures derived in accordance with U.S. GAAP. Accordingly, you should consider Adjusted EBITDA along with other financial performance measures, including net income, and our financial results presented in accordance with U.S. GAAP. Other companies, including companies in our industry, may calculate Adjusted EBITDA differently or not at all, which reduces its usefulness as a comparative measure. We understand that although Adjusted EBITDA is frequently used by securities analysts, lenders and others in their evaluation of companies, Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations are: Adjusted EBITDA does not reflect our cash expenditures or future requirements for capital expenditures or contractual commitments; Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; and although depreciation and amortization are a non-cash charges, the assets being depreciated will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements.
We believe that Adjusted EBITDA is a useful measure for analyzing the performance of our core business because it facilitates operating performance comparisons from period to period and company to company by backing out potential differences caused by changes in foreign exchange rates that impact financial assets and liabilities denominated in currencies other than the U.S. dollar, tax positions (such as the impact on periods or companies of changes in effective tax rates), the age and book depreciation of fixed assets (affecting relative depreciation expense), amortization of intangible assets, stock-based compensation expense (because it is a non-cash expense) and non-recurring items as explained below.
The following reconciliation of net loss to Adjusted EBITDA for the years presented:
| Venus Concept Inc. | ||||||||||||||||
| Reconciliation of Net loss to Non-GAAP Adjusted EBITDA | ||||||||||||||||
| (In thousands of U.S. dollars) | ||||||||||||||||
| Three months ended December 31, | Twelve months ended December 31, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Reconciliation of net loss to adjusted EBITDA | ||||||||||||||||
| Net loss | $ | (15,029 | ) | $ | (22,735 | ) | $ | (82,818 | ) | $ | (42,295 | ) | ||||
| Foreign exchange (gain) loss | (4,277 | ) | 2,202 | (68 | ) | 2,611 | ||||||||||
| Loss on debt extinguishment | 1,821 | 1,645 | 2,938 | - | ||||||||||||
| Loss on disposal of subsidiaries | 2,938 | - | 2,526 | - | ||||||||||||
| Finance expenses | 2,047 | - | 8,343 | 7,549 | ||||||||||||
| Income tax expense | 2,191 | 990 | 1,181 | 1,857 | ||||||||||||
| Depreciation and amortization | 1,109 | 976 | 4,804 | 2,040 | ||||||||||||
| Stock-based compensation expense | 535 | 426 | 2,138 | 2,158 | ||||||||||||
| Goodwill impairment charge | - | - | 27,450 | - | ||||||||||||
| COVID-19 related bad debts | 5,430 | - | 11,088 | - | ||||||||||||
| Other adjustments (1) | 845 | 4,953 | 2,280 | 13,553 | ||||||||||||
| Adjusted EBITDA | $ | (2,390 | ) | $ | (11,543 | ) | $ | (20,138 | ) | $ | (12,527 | ) | ||||
(1) For the year ended December 31, 2020, the other adjustments are represented by severance and retention payments (
FAQ
What were the financial results for Venus Concept for Q4 2020?
What is the revenue guidance for Venus Concept in 2021?
How did the operating loss change for Venus Concept in Q4 2020?
What was Venus Concept's net loss for the fourth quarter of 2020?
How much cash did Venus Concept have at the end of 2020?
